Novo pulling Tresiba in Germany

Novo Nordisk A/S (CSE:NVO; NYSE:NVO) said Wednesday it will no longer market Tresiba insulin degludec in Germany after failing to agree on a price with Germany's Statutory Health Insurance Funds Association (GKV-Spitzenverband).

Novo EVP of China, Pacific & Marketing Jakob Riis told BioCentury the company markets Tresiba at a price of about EUR 2.50 per day and that GKV-Spitzenverband offered less than EUR 1 per day. ...